COVID 19: Resveratrol as a Potential Supplement to Mitigate the Cardiotoxicity Associated with Chloroquine and Hydroxychloroquine Treatment

Abstract

The challenges of SARS-CoV-2 have frightened the world due to a lack of effective treatment. Many clinicians have adopted drug repositioning because of the urgent need to contain the viral pandemic. Several studies have demonstrated the in vitro and in vivo antiviral efficacy of chloroquine and hydroxychloroquine in the treatment of SARS-CoV-2. However, the cardiovascular toxicity of chloroquine and hydroxychloroquine stand as a limitation to their general use to treat SARS-CoV-2. Thus, it is necessitated the search for an adjuvant that could be used alongside these treatments to mitigate the undesired effect. The cardioprotective activity of resveratrol could serve to mitigate the cardiovascular toxicity of chloroquine and hydroxychloroquine. Its antioxidant and anti-inflammatory properties synergistically with chloroquine or hydroxychloroquine could also mitigate the antiviral activity of SARS-CoV-2. In this review, we explore chloroquine and hydroxychloroquine for SARS-CoV-2 treatment and suggest their synergetic use with resveratrol as a recommended therapy to mitigate cardiovascular toxicity and contribute to their antiviral effects.